Mª Ãngeles Muñoz-FernÃ;ndez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2784209/publications.pdf

Version: 2024-02-01

327 papers

8,842 citations

44069 48 h-index 91884 69 g-index

343 all docs

343 docs citations

times ranked

343

10065 citing authors

#	Article	IF	CITATIONS
1	Baseline and <scp>timeâ€updated</scp> factors in preclinical development of anionic dendrimers as successful <scp>antiâ€HIV</scp> â€1 vaginal microbicides. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1774.	6.1	5
2	Poly I:C and STING agonistâ€primed DC increase lymphoid tissue polyfunctional HIVâ€1â€specific CD8 ⁺ T cells and limit CD4 ⁺ Tâ€cell loss in BLT mice. European Journal of Immunology, 2022, 52, 447-461.	2.9	7
3	Targeting the Gut Microbiota of Vertically HIV-Infected Children to Decrease Inflammation and Immunoactivation: A Pilot Clinical Trial. Nutrients, 2022, 14, 992.	4.1	6
4	Safety of G2-S16 Polyanionic Carbosilane Dendrimer as Possible HIV-1 Vaginal Microbicide. International Journal of Molecular Sciences, 2022, 23, 2565.	4.1	1
5	Prevention of Herpesviridae Infections by Cationic PEGylated Carbosilane Dendrimers. Pharmaceutics, 2022, 14, 536.	4.5	1
6	Impact of Gestational COVID-19 on Neonatal Outcomes. Pediatric Infectious Disease Journal, 2022, 41, 466-472.	2.0	22
7	Safety and efficacy of G2-S16 dendrimer as microbicide in healthy human vaginal tissue explants. Journal of Nanobiotechnology, 2022, 20, 151.	9.1	2
8	High Plasma sTNF-R1 Level Is Related to Loss of Natural HIV Control in Long-Term Elite Controllers. Frontiers in Cellular and Infection Microbiology, 2022, 12, 858872.	3.9	1
9	Engineered Neutral Phosphorous Dendrimers Protect Mouse Cortical Neurons and Brain Organoids from Excitotoxic Death. International Journal of Molecular Sciences, 2022, 23, 4391.	4.1	6
10	miRNA Profile Based on ART Delay in Vertically Infected HIV-1 Youths Is Associated With Inflammatory Biomarkers and Activation and Maturation Immune Levels. Frontiers in Immunology, 2022, 13, 878630.	4.8	3
11	HIV HGM biobank as a research platform for paediatric infectious diseases and COVID-19 pandemic. AIDS Research and Therapy, 2022, 19, .	1.7	1
12	Coronavirus Disease (COVID-19): A Perspective from Immunosenescence. , 2021, 12, 3.		11
13	The clinical relevance of the microbiome when managing paediatric infectious diseases—Narrative review. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 441-449.	1.5	0
14	Clinical, Immunological, and Virological Outcomes Among Youths With Perinatal HIV After Transition to Adult Units in Spain From 1997 to 2016. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 240-247.	2.1	8
15	Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure. Journal of Antimicrobial Chemotherapy, 2021, 76, 1886-1892.	3.0	1
16	Nanotechnology against human cytomegalovirus in vitro: polyanionic carbosilane dendrimers as antiviral agents. Journal of Nanobiotechnology, 2021, 19, 65.	9.1	9
17	BMS Derivatives C7â€Linked to βâ€Cyclodextrin and Hyperbranched Polyglycerol Retain Activity against R5â€HIVâ€1 NLAD8 Isolates and Can Be Deemed Potential Microbicides. ChemMedChem, 2021, 16, 2217-2222.	3.2	1
18	Longitudinal plasma cytokine concentrations and recurrent wheezing after RSV bronchiolitis. Cytokine, 2021, 140, 155434.	3.2	2

#	Article	IF	Citations
19	Promising PEGylated cationic dendrimers for delivery of miRNAs as a possible therapy against HIV-1 infection. Journal of Nanobiotechnology, 2021, 19, 158.	9.1	10
20	Role of G2-S16 Polyanionic Carbosilane Dendrimer in the Prevention of Respiratory Syncytial Virus Infection In Vitro and In Vivo in Mice. Polymers, 2021, 13, 2141.	4.5	2
21	Early antiretroviral therapy initiation effect on metabolic profile in vertically HIV-1-infected children. Journal of Antimicrobial Chemotherapy, 2021, 76, 2993-3001.	3.0	6
22	G2-S16 Polyanionic Carbosilane Dendrimer Can Reduce HIV-1 Reservoir Formation by Inhibiting Macrophage Cell to Cell Transmission. International Journal of Molecular Sciences, 2021, 22, 8366.	4.1	1
23	A Review on the Current Knowledge on ZIKV Infection and the Interest of Organoids and Nanotechnology on Development of Effective Therapies against Zika Infection. International Journal of Molecular Sciences, 2021, 22, 35.	4.1	13
24	Innate and adaptive abnormalities in youth with vertically acquired HIV through a multicentre cohort in Spain. Journal of the International AIDS Society, 2021, 24, e25804.	3.0	13
25	The Role of BMP Signaling in Female Reproductive System Development and Function. International Journal of Molecular Sciences, 2021, 22, 11927.	4.1	13
26	How well are we performing the initial assessment of HIVâ€positive patients? Results from a multicentre cohort in Spain. HIV Medicine, 2020, 21, 128-134.	2.2	0
27	Near normalization of peripheral blood markers in HIV-infected patients on long-term suppressive antiretroviral therapy: a case–control study. Aids, 2020, 34, 1891-1897.	2.2	4
28	Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine. Pharmaceutics, 2020, 12, 656.	4.5	12
29	Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study. Nutrients, 2020, 12, 2112.	4.1	10
30	Evaluation of pH-dependent amphiphilic carbosilane dendrons in micelle formation, drug loading and HIV-1 infection. Organic and Biomolecular Chemistry, 2020, 18, 9639-9652.	2.8	4
31	Nanosystems Applied to HIV Infection: Prevention and Treatments. International Journal of Molecular Sciences, 2020, 21, 8647.	4.1	10
32	Increased Frequencies of Myeloid-Derived Suppressor Cells Precede Immunodiscordance in HIV-Infected Subjects. Frontiers in Immunology, 2020, 11, 581307.	4.8	6
33	High Preventive Effect of G2-S16 Anionic Carbosilane Dendrimer against Sexually Transmitted HSV-2 Infection. Molecules, 2020, 25, 2965.	3.8	9
34	Dendrimers toward Translational Nanotherapeutics: Concise Key Step Analysis. Bioconjugate Chemistry, 2020, 31, 2060-2071.	3.6	38
35	Emergence of Nanotechnology to Fight HIV Sexual Transmission: The Trip of G2-S16 Polyanionic Carbosilane Dendrimer to Possible Pre-Clinical Trials. International Journal of Molecular Sciences, 2020, 21, 9403.	4.1	13
36	Analysis of ALS-related proteins during herpes simplex virus-2 latent infection. Journal of Neuroinflammation, 2020, 17, 371.	7.2	14

#	Article	IF	Citations
37	New synthetic procedure for the antiviral sulfonate carbosilane dendrimer G2-S16 and its fluorescein-labelled derivative for biological studies. RSC Advances, 2020, 10, 20083-20088.	3.6	6
38	Frailty, markers of immune activation and oxidative stress in HIV infected elderly. PLoS ONE, 2020, 15, e0230339.	2.5	18
39	Cationic Dendrimer G2-S16 Inhibits Herpes Simplex Type 2 Infection and Protects Mice Vaginal Microbiome. Pharmaceutics, 2020, 12, 515.	4.5	10
40	Gold Nanoparticles Crossing Blood-Brain Barrier Prevent HSV-1 Infection and Reduce Herpes Associated Amyloid-βsecretion. Journal of Clinical Medicine, 2020, 9, 155.	2.4	25
41	Assessing and measuring financial sustainability model of the Spanish HIV HGM BioBank. Journal of Translational Medicine, 2020, 18, 6.	4.4	10
42	Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound. Scientific Reports, 2020, 10, 22286.	3.3	6
43	Brief Report: CYP27B1 rs10877012 T Allele Was Linked to Non-AIDS Progression in ART-NaÃ ⁻ ve HIV-Infected Patients: A Retrospective Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 659-664.	2.1	2
44	Prognostic factors of a lower CD4/CD8 ratio in long term viral suppression HIV infected children. PLoS ONE, 2019, 14, e0220552.	2.5	5
45	Synthesis of bow-tie carbosilane dendrimers and their HIV antiviral capacity: A comparison of the dendritic topology on the biological process. European Polymer Journal, 2019, 119, 200-212.	5.4	13
46	Dendritic Cells, the Double Agent in the War Against HIV-1. Frontiers in Immunology, 2019, 10, 2485.	4.8	34
47	Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015. PLoS ONE, 2019, 14, e0223536.	2.5	6
48	DBP rs 16846876 and rs 12512631 polymorphisms are associated with progression to AIDS na \tilde{A} -ve HIV-infected patients: a retrospective study. Journal of Biomedical Science, 2019, 26, 83.	7.0	2
49	G2-S16 dendrimer microbicide does not interfere with the vaginal immune system. Journal of Nanobiotechnology, 2019, 17, 65.	9.1	8
50	Dendronized magnetic nanoparticles for HIV-1 capture and rapid diagnostic. Colloids and Surfaces B: Biointerfaces, 2019, 181, 360-368.	5.0	22
51	Hepatitis C virus and cumulative infections are associated with atherogenic cardiovascular events in HIV-infected subjects. Antiviral Research, 2019, 169, 104527.	4.1	4
52	Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment. Journal of Nanobiotechnology, 2019, 17, 69.	9.1	20
53	<p>G1-S4 or G2-S16 carbosilan dendrimer in combination with Platycodin D as a promising vaginal microbicide candidate with contraceptive activity</p> . International Journal of Nanomedicine, 2019, Volume 14, 2371-2381.	6.7	15
54	VDR rs2228570 Polymorphism Is Related to Non-Progression to AIDS in Antiretroviral Therapy Na \tilde{A} -ve HIV-Infected Patients. Journal of Clinical Medicine, 2019, 8, 311.	2.4	9

#	Article	IF	Citations
55	Poly(N-vinylcaprolactam) Nanogels with Antiviral Behavior against HIV-1 Infection. Scientific Reports, 2019, 9, 5732.	3.3	26
56	New anionic poly(alkylideneamine) dendrimers as microbicide agents against HIV-1 infection. Nanoscale, 2019, 11, 9679-9690.	5.6	33
57	Combination of G2-S16 dendrimer/dapivirine antiretroviral as a new HIV-1 microbicide. Future Medicinal Chemistry, 2019, 11, 3005-3013.	2.3	9
58	Reduced Time to Suppression Among Neonates With HIV Initiating Antiretroviral Therapy Within 7 Days After Birth. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 483-490.	2.1	7
59	Dendrimers as a Candidate for Microbicide in Prevention of HIV-1 Infection in Women: Steps toward Their Clinical Evaluation., 2019, , 173-205.		0
60	Specific Patterns of T Cell Immunosenescence in Vertically HIV-Infected Subjects., 2019, , 1865-1882.		0
61	Sulfonate-ended carbosilane dendrimers with a flexible scaffold cause inactivation of HIV-1 virions and gp120 shedding. Nanoscale, 2018, 10, 8998-9011.	5.6	20
62	HIVâ€1 increases extracellular amyloidâ€beta levels through neprilysin regulation in primary cultures of human astrocytes. Journal of Cellular Physiology, 2018, 234, 5880-5887.	4.1	9
63	Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers. BMC Medicine, 2018, 16, 30.	5.5	19
64	Anionic Carbosilane Dendrimers Destabilize the GP120-CD4 Complex Blocking HIV-1 Entry and Cell to Cell Fusion. Bioconjugate Chemistry, 2018, 29, 1584-1594.	3.6	26
65	Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	4
66	Association of heterozygous CCR5î"32 deletion with survival in HIV-infection: A cohort study. Antiviral Research, 2018, 150, 15-19.	4.1	6
67	Study of non-covalent interactions on dendriplex formation: Influence of hydrophobic, electrostatic and hydrogen bonds interactions. Colloids and Surfaces B: Biointerfaces, 2018, 162, 380-388.	5.0	7
68	Early and Highly Suppressive Antiretroviral Therapy Are Main Factors Associated With Low Viral Reservoir in European Perinatally HIV-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 269-276.	2.1	57
69	Paediatric research in Spain: Challenges and priorities. INVEST-AEP Platform. Anales De PediatrÃa (English Edition), 2018, 89, 314.e1-314.e6.	0.2	0
70	Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance—Supercontrollers. Frontiers in Immunology, 2018, 9, 2897.	4.8	15
71	Sleep Profile and Self-Reported Neuropsychiatric Symptoms in Vertically HIV-Infected Adolescents on cART. Journal of Pediatric Infectious Diseases, 2018, 13, 300-307.	0.2	6
72	Specific Patterns of T Cell Immunosenescence in Vertically HIV-Infected Subjects., 2018, , 1-18.		O

#	Article	IF	CITATIONS
73	Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. Journal of Antimicrobial Chemotherapy, 2018, 73, 1940-1948.	3.0	19
74	HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and $\hat{1}\pm4\hat{1}^27$ on CD4 T-Cells Prior Therapy Initiation. Frontiers in Immunology, 2018, 9, 1673.	4.8	7
75	Estrogen Receptor-Alpha (ESR1) Governs the Lower Female Reproductive Tract Vulnerability to Candida albicans. Frontiers in Immunology, 2018, 9, 1033.	4.8	22
76	High Plasma Levels of sTNF-R1 and CCL11 Are Related to CD4+ T-Cells Fall in Human Immunodeficiency Virus Elite Controllers With a Sustained Virologic Control. Frontiers in Immunology, 2018, 9, 1399.	4.8	3
77	Dendrimer-protein interactions versus dendrimer-based nanomedicine. Colloids and Surfaces B: Biointerfaces, 2017, 152, 414-422.	5.0	42
78	Isolation Methods of Peripheral Blood Mononuclear Cells in Spanish Biobanks: An Overview. Biopreservation and Biobanking, 2017, 15, 305-309.	1.0	13
79	G2-S16 dendrimer as a candidate for a microbicide to prevent HIV-1 infection in women. Nanoscale, 2017, 9, 9732-9742.	5.6	25
80	Rapid Decrease in Peripheral Blood Mononucleated Cell Telomere Length After HIV Seroconversion, but Not HCV Seroconversion. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, e29-e32.	2.1	20
81	Relationship between CCR5(WT/Δ32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection. Clinical Microbiology and Infection, 2017, 23, 318-324.	6.0	5
82	Gold nanoparticles stabilized by cationic carbosilane dendrons: synthesis and biological properties. Dalton Transactions, 2017, 46, 8736-8745.	3.3	25
83	New diagnoses of human immunodeficiency virus infection in the Spanish pediatric HIV Cohort (CoRISpe) from 2004 to 2013. Medicine (United States), 2017, 96, e7858.	1.0	7
84	Carbosilane dendrons with fatty acids at the core as a new potential microbicide against HSV-2/HIV-1 co-infection. Nanoscale, 2017, 9, 17263-17273.	5.6	19
85	New anionic carbosilane dendrons functionalized with a DO3A ligand at the focal point for the prevention of HIV-1 infection. Antiviral Research, 2017, 146, 54-64.	4.1	8
86	<i>IL7RA</i> polymorphisms are not associated with AIDS progression. European Journal of Clinical Investigation, 2017, 47, 719-727.	3.4	3
87	Low Bone Mineral Density in Vertically HIV-infected Children and Adolescents. Pediatric Infectious Disease Journal, 2017, 36, 578-583.	2.0	17
88	Polyanionic carbosilane dendrimers prevent hepatitis C virus infection in cell culture. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 49-58.	3.3	38
89	Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression. Clinical Infectious Diseases, 2017, 64, 1191-1197.	5.8	30
90	CCR5+ CD8 T-cell levels and monocyte activation precede the onset of acute coronary syndrome in HIV-infected patients on antiretroviral therapy. Thrombosis and Haemostasis, 2017, 117, 1141-1149.	3.4	9

#	Article	IF	CITATIONS
91	Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens. Journal of Translational Medicine, 2017, 15, 259.	4.4	6
92	Multi-Target Inhibition of Cancer Cell Growth by SiRNA Cocktails and 5-Fluorouracil Using Effective Piperidine-Terminated Phosphorus Dendrimers. Colloids and Interfaces, 2017, 1, 6.	2.1	26
93	Efficacy of carbosilane dendrimers with an antiretroviral combination against HIV-1 in the presence of semen-derived enhancer of viral infection. European Journal of Pharmacology, 2017, 811, 155-163.	3.5	23
94	CD81 association with SAMHD1 enhances HIV-1 reverse transcription by increasing dNTP levels. Nature Microbiology, 2017, 2, 1513-1522.	13.3	34
95	Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. PLoS ONE, 2017, 12, e0186602.	2.5	20
96	Antiviral mechanism of polyanionic carbosilane dendrimers against HIV-1. International Journal of Nanomedicine, 2016, 11, 1281.	6.7	35
97	Nanotechnology as a New Therapeutic Approach to Prevent the HIV-Infection of Treg Cells. PLoS ONE, 2016, 11, e0145760.	2.5	11
98	Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: mechanism of antiviral action. International Journal of Nanomedicine, 2016, 11, 2147.	6.7	25
99	Efficacy of HIV antiviral polyanionic carbosilane dendrimer G2-S16 in the presence of semen. International Journal of Nanomedicine, 2016, 11, 2443.	6.7	20
100	Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination. Aids, 2016, 30, 553-562.	2.2	6
101	Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. Aids, 2016, 30, 1385-1392.	2.2	167
102	Dendronized Anionic Gold Nanoparticles: Synthesis, Characterization, and Antiviral Activity. Chemistry - A European Journal, 2016, 22, 2987-2999.	3.3	40
103	Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw462.	3.0	9
104	Pediatric Extrapulmonary Tuberculosis. Pediatric Infectious Disease Journal, 2016, 35, 1175-1181.	2.0	53
105	HIV-1 increases TLR responses in human primary astrocytes. Scientific Reports, 2016, 5, 17887.	3.3	25
106	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004–2013. Journal of Infection, 2016, 72, 587-596.	3.3	60
107	The effect of polyethylene glycol-modified lipids on the interaction of HIV-1 derived peptide–dendrimer complexes with lipid membranes. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 3005-3016.	2.6	7
108	Dendronized PLGA nanoparticles with anionic carbosilane dendrons as antiviral agents against HIV infection. RSC Advances, 2016, 6, 73817-73826.	3.6	4

#	Article	IF	Citations
109	Improved Efficiency of Ibuprofen by Cationic Carbosilane Dendritic Conjugates. Molecular Pharmaceutics, 2016, 13, 3427-3438.	4.6	15
110	Effect of Several HIV Antigens Simultaneously Loaded with G2-NN16 Carbosilane Dendrimer in the Cell Uptake and Functionality of Human Dendritic Cells. Bioconjugate Chemistry, 2016, 27, 2844-2849.	3.6	8
111	Dendrimeric based microbicides against sexual transmitted infections associated to heparan sulfate. RSC Advances, 2016, 6, 46755-46764.	3.6	13
112	Immunisation practices in centres caring for children with perinatally acquired HIV: A call for harmonisation. Vaccine, 2016, 34, 5587-5594.	3.8	2
113	Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure. Antimicrobial Agents and Chemotherapy, 2016, 60, 6398-6401.	3.2	0
114	Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects. Clinical Microbiology and Infection, 2016, 22, 461.e1-461.e5.	6.0	10
115	Monocyte Phenotype and Polyfunctionality Are Associated With Elevated Soluble Inflammatory Markers, Cytomegalovirus Infection, and Functional and Cognitive Decline in Elderly Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 610-618.	3.6	33
116	Phenotype and Polyfunctional Deregulation Involving Interleukin 6 (IL-6)– and IL-10–Producing Monocytes in HIV-Infected Patients Receiving Combination Antiretroviral Therapy Differ From Those in Healthy Older Individuals. Journal of Infectious Diseases, 2016, 213, 999-1007.	4.0	14
117	Disease disclosure, treatment adherence, and behavioural profile in a cohort of vertically acquired HIV-infected adolescents. NeuroCoRISpeS study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 124-130.	1.2	25
118	Sex Hormones Coordinate Neutrophil Immunity in the Vagina by Controlling Chemokine Gradients. Journal of Infectious Diseases, 2016, 213, 476-484.	4.0	33
119	Polycationic carbosilane dendrimer decreases angiogenesis and tumor-associated macrophages in tumor-bearing mice. RSC Advances, 2015, 5, 104110-104115.	3.6	2
120	Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1. Scientific Reports, 2015, 5, 16445.	3.3	41
121	Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism. Scientific Reports, 2015, 5, 12442.	3.3	53
122	Single Nucleotide Polymorphisms of CXCL9-11 Chemokines Are Associated With Liver Fibrosis in HIV/HCV-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 386-395.	2.1	11
123	WNT Signaling Suppression in the Senescent Human Thymus. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 273-281.	3.6	23
124	HIV-1 antiviral behavior of anionic PPI metallo-dendrimers withÂEDAÂcore. European Journal of Medicinal Chemistry, 2015, 98, 139-148.	5.5	26
125	Prevention vaginally of HIV-1 transmission in humanized BLT mice and mode of antiviral action of polyanionic carbosilane dendrimer G2-S16. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1299-1308.	3.3	52
126	Living to suffer? Quality of life factors associated with adherence to antiretroviral therapy in Spanish HIV-infected children. Vulnerable Children and Youth Studies, 2015, 10, 163-177.	1.1	1

#	Article	IF	CITATIONS
127	Use of carbosilane dendrimer to switch macrophage polarization for the acquisition of antitumor functions. Nanoscale, 2015, 7, 3857-3866.	5.6	36
128	In vivo delivery of siRNA to the brain by carbosilane dendrimer. Journal of Controlled Release, 2015, 200, 60-70.	9.9	98
129	Fluorescein labelled cationic carbosilane dendritic systems for biological studies. European Polymer Journal, 2015, 71, 61-72.	5.4	24
130	Specific Legislation on Biobanks in Spain. Biopreservation and Biobanking, 2015, 13, 207-211.	1.0	13
131	Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission. Lancet Infectious Diseases, The, 2015, 15, 1108-1114.	9.1	34
132	Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. BMC Infectious Diseases, 2015, 15, 119.	2.9	33
133	Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission. Nanomedicine, 2015, 10, 899-914.	3.3	44
134	Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (B). Efficiency of pharmacological action. International Journal of Pharmaceutics, 2015, 485, 288-294.	5. 2	71
135	Polyanionic carbosilane dendrimer-conjugated antiviral drugs as efficient microbicides: Recent trends and developments in HIV treatment/therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1481-1498.	3.3	60
136	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. Journal of Antimicrobial Chemotherapy, 2015, 70, 1833-1842.	3.0	56
137	Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal. Antiviral Research, 2015, 123, 163-171.	4.1	10
138	Anti-Human Immunodeficiency Virus Activity of Thiol-Ene Carbosilane Dendrimers and Their Potential Development as a Topical Microbicide. Journal of Biomedical Nanotechnology, 2015, 11, 1783-1798.	1.1	19
139	Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides. Nanoscale, 2015, 7, 14669-14683.	5.6	33
140	IFNÎ ³ ^{â^'} TNFα ^{â^'} IL2 ^{â^'} MIP1α ^{â^'} CD107a ⁺ PRF1 <s -="" 1210-1218.<="" 2015,="" 70,="" a="" and="" associated="" biological="" death="" elderly="" gerontology="" humans.="" in="" independently="" is="" journals="" medical="" of="" pp65-specific="" response="" sciences="" sciences,="" series="" t-cell="" td="" time="" to="" with=""><td>up>+3.6</td><td>p>CD8 11</td></s>	up>+3.6	p>CD8 11
141	Bifunctional Chelating Agents Based on Ionic Carbosilane Dendrons with DO3A at the Focal Point and Their Complexation Behavior with Copper(II). Inorganic Chemistry, 2015, 54, 8943-8956.	4.0	10
142	A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. PLoS ONE, 2015, 10, e0141456.	2.5	24
143	A Conserved GPG-Motif in the HIV-1 Nef Core Is Required for Principal Nef-Activities. PLoS ONE, 2015, 10, e0145239.	2.5	2
144	Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells:â€,a possibility for HIV-1 paediatric patients?. Journal of Virus Eradication, 2015, 1, 148-52.	0.5	2

#	Article	IF	CITATIONS
145	Enhanced activity of carbosilane dendrimers against HIV when combined with reverse transcriptase inhibitor drugs: searching for more potent microbicides. International Journal of Nanomedicine, 2014, 9, 3591.	6.7	20
146	Prostaglandin E2 Reduces the Release and Infectivity of New Cell-Free Virions and Cell-To-Cell HIV-1 Transfer. PLoS ONE, 2014, 9, e85230.	2.5	15
147	Determinants of Highly Active Antiretroviral Therapy Duration in HIV-1-Infected Children and Adolescents in Madrid, Spain, from 1996 to 2012. PLoS ONE, 2014, 9, e96307.	2.5	7
148	CCR5/CD4/CXCR4 oligomerization prevents HIV-1 gp120 _{IIIB} binding to the cell surface. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1960-9.	7.1	45
149	Subclinical Atherosclerosis and Markers of Immune Activation in HIV-Infected Children and Adolescents. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 42-49.	2.1	53
150	Induction of <scp>T</scp> reg cells after oral immunotherapy in hen's eggâ€allergic children. Pediatric Allergy and Immunology, 2014, 25, 103-106.	2.6	14
151	Functionally Defective High-Density Lipoproteins Are Related to Heightened T-Cell Activation in Vertically HIV-Infected Adolescents. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 265-269.	2.1	1
152	HIV-1 induces B-cell activation and class switch recombination via spleen tyrosine kinase and c-Jun N-terminal kinase pathways. Aids, 2014, 28, 2365-2374.	2.2	3
153	TNF-Â levels in HIV-infected patients after long-term suppressive cART persist as high as in elderly, HIV-uninfected subjects. Journal of Antimicrobial Chemotherapy, 2014, 69, 3041-3046.	3.0	46
154	Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation. Nanomedicine, 2014, 9, 2683-2702.	3.3	17
155	Carbosilane dendrimers as gene delivery agents for the treatment of HIV infection. Journal of Controlled Release, 2014, 184, 51-57.	9.9	58
156	Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer. International Journal of Pharmaceutics, 2014, 461, 391-402.	5.2	24
157	Synergistic activity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antiretrovirals as topical anti-HIV-1 microbicide. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 609-618.	3.3	49
158	Polyanionic Functionalized Carbosilane Dendrimers as Potential Microbicides to Prevent HIV-1 Sexual Transmission. AIDS Research and Human Retroviruses, 2014, 30, A204-A204.	1.1	2
159	Bryostatin Activates HIV-1 Latent Expression in Human Astrocytes through a PKC and NF-kB-Dependent Mechanism. AIDS Research and Human Retroviruses, 2014, 30, A285-A285.	1.1	2
160	Broad-spectrum Anti-HIV-1 Activity of Anionic Carbosilane Dendrimers and Synergy in Combination with Maraviroc and Tenofovir as Topical Microbicide. AIDS Research and Human Retroviruses, 2014, 30, A144-A144.	1.1	1
161	Synthesis of new anionic carbosilane dendrimers via thiol–ene chemistry and their antiviral behaviour. Organic and Biomolecular Chemistry, 2014, 12, 3222.	2.8	41
162	Maraviroc Reduces the Regulatory T-Cell Frequency in Antiretroviral-Naive HIV-Infected Subjects. Journal of Infectious Diseases, 2014, 210, 890-898.	4.0	23

#	Article	IF	Citations
163	Interference of cationic polymeric nanoparticles with clinical chemistry testsâ€"Clinical relevance. International Journal of Pharmaceutics, 2014, 473, 599-606.	5.2	15
164	Interaction of phosphorus dendrimers with HIV peptidesâ€"Fluorescence studies of nano-complexes formation. Journal of Luminescence, 2014, 148, 364-369.	3.1	9
165	Amphiphilic Cationic Carbosilane–PEG Dendrimers: Synthesis and Applications in Gene Therapy. European Journal of Medicinal Chemistry, 2014, 76, 43-52.	5.5	35
166	Cardiovascular biomarkers in vertically HIV-infected children without metabolic abnormalities. Atherosclerosis, 2014, 233, 410-414.	0.8	20
167	HIV Infection Deregulates the Balance Between Regulatory T Cells and IL-2–Producing CD4 T Cells by Decreasing the Expression of the IL-2 Receptor in Treg. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 278-282.	2.1	15
168	ACSM4 Polymorphisms Are Associated With Rapid AIDS Progression in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 27-32.	2.1	8
169	Quantifying the use of bioresources for promoting their sharing in scientific research. GigaScience, 2013, 2, 7.	6.4	38
170	Theoretical analysis of the neuraminidase epitope of the Mexican A H1N1 influenza strain, and experimental studies on its interaction with rabbit and human hosts. Immunologic Research, 2013, 56, 44-60.	2.9	17
171	Glycodendrimers as new tools in the search for effective anti-HIV DC-based immunotherapies. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 972-984.	3.3	36
172	Female sex hormones regulate the Th17 immune response to sperm and Candida albicans. Human Reproduction, 2013, 28, 3283-3291.	0.9	28
173	A new chimeric protein represses HIV-1 LTR-mediated expression by DNA methylase. Antiviral Research, 2013, 98, 394-400.	4.1	6
174	Novel â€~SiC' carbosilane dendrimers as carriers for anti-HIV nucleic acids: Studies on complexation and interaction with blood cells. Colloids and Surfaces B: Biointerfaces, 2013, 109, 183-189.	5.0	40
175	Complexation of HIV derived peptides with carbosilane dendrimers. Colloids and Surfaces B: Biointerfaces, 2013, 101, 236-242.	5.0	40
176	The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. Journal of Infection, 2013, 66, 57-66.	3.3	120
177	Specific patterns of CD4-associated immunosenescence in vertically HIV-infected subjects. Clinical Microbiology and Infection, 2013, 19, 558-565.	6.0	23
178	HIV infection of human regulatory T cells downregulates Foxp3 expression by increasing DNMT3b levels and DNA methylation in the FOXP3 gene. Aids, 2013, 27, 2019-2029.	2.2	64
179	Long-Term Suppressive Combined Antiretroviral Treatment Does Not Normalize the Serum Level of Soluble CD14. Journal of Infectious Diseases, 2013, 207, 1221-1225.	4.0	69
180	Actin-binding Protein Drebrin Regulates HIV-1-triggered Actin Polymerization and Viral Infection. Journal of Biological Chemistry, 2013, 288, 28382-28397.	3.4	28

#	Article	IF	CITATIONS
181	Estradiol downregulates NF- $\hat{\mathbb{P}}$ b translocation by Ikbkg transcriptional repression in dendritic cells. Genes and Immunity, 2013, 14, 462-469.	4.1	15
182	Study of cationic carbosilane dendrimers as potential activating stimuli in macrophages. RSC Advances, 2013, 3, 23445.	3.6	10
183	The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. Aids, 2013, 27, 1513-1516.	2.2	125
184	Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment. Aids, 2013, 27, 2081-2088.	2.2	13
185	TNF-Î' May Mediate Inflammasome Activation in the Absence of Bacterial Infection in More than One Way. PLoS ONE, 2013, 8, e71477.	2.5	53
186	Predictors of Attrition and Immunological Failure in HIV-1 Patients on Highly Active Antiretroviral Therapy from Different Healthcare Settings in Mozambique. PLoS ONE, 2013, 8, e82718.	2.5	21
187	Biophysical Characterization of Glycodendrimers As Nano-carriers for HIV Peptides. Current Medicinal Chemistry, 2013, 20, 3935-3943.	2.4	17
188	Differential Gag-Specific Polyfunctional T Cell Maturation Patterns in HIV-1 Elite Controllers. Journal of Virology, 2012, 86, 3667-3674.	3.4	52
189	Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. Journal of Antimicrobial Chemotherapy, 2012, 67, 1228-1237.	3.0	29
190	The PDZ-adaptor protein syntenin-1 regulates HIV-1 entry. Molecular Biology of the Cell, 2012, 23, 2253-2263.	2.1	31
191	Carbosilane Dendrimers are a Non-Viral Delivery System for Antisense Oligonucleotides: Characterization of Dendriplexes. Journal of Biomedical Nanotechnology, 2012, 8, 57-73.	1.1	34
192	Preterm neonates show marked leukopenia and lymphopenia that are associated with increased regulatory T-cell values and diminished IL-7. Pediatric Research, 2012, 71, 590-597.	2.3	71
193	HIV-1 Tropism Evolution after Short-Term Maraviroc Monotherapy in HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy, 2012, 56, 3981-3983.	3.2	7
194	The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. Aids, 2012, 26, 1885-1894.	2.2	67
195	Detectable Viral Load Aggravates Immunosenescence Features of CD8 T-Cell Subsets in Vertically HIV-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 447-454.	2.1	20
196	Prevalence of Transmitted HIV-1 Drug Resistance Mutations in Children and Adolescents in São Paulo, Brazil. Pediatric Infectious Disease Journal, 2012, 31, e255-e257.	2.0	21
197	Sulfonilamidothiopyrimidone and thiopyrimidone derivatives as selective COX-2 inhibitors: Synthesis, biological evaluation, and docking studies. European Journal of Medicinal Chemistry, 2012, 57, 149-161.	5.5	13
198	Polyanionic N-donor ligands as chelating agents in transition metal complexes: synthesis, structural characterization and antiviral properties against HIV. Dalton Transactions, 2012, 41, 6488.	3.3	18

#	Article	IF	CITATIONS
199	Synthesis, structure and molecular modelling of anionic carbosilane dendrimers. Dalton Transactions, 2012, 41, 12733.	3.3	45
200	Carbosilane Dendrimer 2G-NN16 Represses Tc17 Differentiation in Primary T CD8+ Lymphocytes. Molecular Pharmaceutics, 2012, 9, 102-110.	4.6	12
201	Direct Phenotypical and Functional Dysregulation of Primary Human B Cells by Human Immunodeficiency Virus (HIV) Type 1 In Vitro. PLoS ONE, 2012, 7, e39472.	2.5	14
202	High Drug Resistance Prevalence among Vertically HIV-Infected Patients Transferred from Pediatric Care to Adult Units in Spain. PLoS ONE, 2012, 7, e52155.	2.5	31
203	HIVâ€1 infection and neurocognitive impairment in the current era. Reviews in Medical Virology, 2012, 22, 33-45.	8.3	47
204	The inhibition of Th17 immune response inÂvitro and inÂvivo by the carbosilane dendrimer 2G-NN16. Biomaterials, 2012, 33, 4002-4009.	11.4	17
205	PEGylated poly(ethylene imine) copolymer-delivered siRNA inhibits HIV replication in vitro. Journal of Controlled Release, 2012, 157, 55-63.	9.9	45
206	Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile. Journal of Controlled Release, 2012, 161, 949-958.	9.9	82
207	Antiviral Properties Against HIV of Water Soluble Copper Carbosilane Dendrimers and their EPR Characterization. Current Medicinal Chemistry, 2012, 19, 4984-4994.	2.4	27
208	Validation of a Generation 4 Phosphorus-Containing Polycationic Dendrimer for Gene Delivery Against HIV-1. Current Medicinal Chemistry, 2012, 19, 5044-5051.	2.4	49
209	In Vitro Studies of Water-Stable Cationic Carbosilane Dendrimers As Delivery Vehicles for Gene Therapy Against HIV and Hepatocarcinoma. Current Medicinal Chemistry, 2012, 19, 5052-5061.	2.4	34
210	The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens. Journal of Virology, 2011, 85, 11468-11478.	3.4	63
211	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVACO2). Vaccine, 2011, 29, 8309-8316.	3.8	70
212	Recent Achievements in Understanding Immune Recovery of Children Treated with HAART. Current Pediatric Reviews, 2011, 7, 188-198.	0.8	0
213	Causes of Death in Pediatric Patients Vertically Infected by the Human Immunodeficiency Virus Type 1 in Madrid, Spain, From 1982 to Mid-2009. Pediatric Infectious Disease Journal, 2011, 30, 495-500.	2.0	14
214	Hepatitis C virus replication in Caucasian HIV controllers. Journal of Viral Hepatitis, 2011, 18, e350-7.	2.0	29
215	Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy. HIV Medicine, 2011, 12, 54-60.	2.2	12
216	Discordance rates between Trofile \hat{A}^{\otimes} test and short-term virological response to maraviroc. Antiviral Research, 2011, 89, 182-185.	4.1	10

#	Article	IF	Citations
217	Transitionâ€Metal Complexes Based on a Sulfonateâ€Containing Nâ€Donor Ligand and Their Use as HIV Antiviral Agents. European Journal of Inorganic Chemistry, 2011, 2011, 1657-1665.	2.0	17
218	Cardiovascular risk markers are increased in HIV-infected children with lipodystrophy syndrome. Journal of Infection, 2011, 62, 240-243.	3.3	4
219	HIV Infection-Related Premature Immunosenescence: High Rates of Immune Exhaustion After Short Time of Infection. Current HIV Research, 2011, 9, 289-294.	0.5	33
220	Sustained virological response to interferon-Â plus ribavirin decreases inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients. Journal of Antimicrobial Chemotherapy, 2011, 66, 645-649.	3.0	29
221	Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain. Journal of Antimicrobial Chemotherapy, 2011, 66, 2362-2371.	3.0	17
222	Virological Response after Short-Term CCR5 Antagonist Exposure in HIV-Infected Patients: Frequency of Subjects with Virological Response and Associated Factors. Antimicrobial Agents and Chemotherapy, 2011, 55, 4664-4669.	3.2	11
223	Estradiol impairs the Th17 immune response against <i>Candida albicans</i> . Journal of Leukocyte Biology, 2011, 91, 159-165.	3.3	41
224	Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected. PLoS ONE, 2011, 6, e27864.	2.5	84
225	Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency. Current HIV Research, 2010, 8, 418-429.	0.5	107
226	ASSOCIATION BETWEEN LIPODYSTROPHY AND LEPTIN IN HUMAN IMMUNODEFICIENCY VIRUS-1-INFECTED CHILDREN RECEIVING LOPINAVIR/RITONAVIR-BASED THERAPY. Pediatric Infectious Disease Journal, 2010, 29, 774-777.	2.0	4
227	Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. Aids, 2010, 24, 2059-2067.	2.2	39
228	Amyloid-β Induces Cyclooxygenase-2 and PGE2 Release in Human Astrocytes in NF-κ B Dependent Manner. Journal of Alzheimer's Disease, 2010, 22, 493-505.	2.6	20
229	Synthesis of carbosilane dendrons and dendrimers derived from 1,3,5-trihydroxybenzene. Tetrahedron, 2010, 66, 9203-9213.	1.9	43
230	Gene Therapy in HIVâ€Infected Cells to Decrease Viral Impact by Using an Alternative Delivery Method. ChemMedChem, 2010, 5, 921-929.	3.2	48
231	Inside Cover: Gene Therapy in HIV-Infected Cells to Decrease Viral Impact by Using an Alternative Delivery Method (ChemMedChem 6/2010). ChemMedChem, 2010, 5, 798-798.	3.2	2
232	Phenotype and functional analysis of human monocytes-derived dendritic cells loaded with a carbosilane dendrimer. Biomaterials, 2010, 31, 8749-8758.	11.4	46
233	Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients?. BMC Infectious Diseases, 2010, 10, 244.	2.9	27
234	Diagnosis of advanced fibrosis in HIV and hepatitis C virus $\hat{a} \in c$ oinfected patients via a new noninvasive index: the HGM $\hat{a} \in c$ index. HIV Medicine, 2010, 11, 64-73.	2.2	13

#	Article	IF	CITATIONS
235	Nuclear factorâ€PB activation regulates cyclooxygenaseâ€2 induction in human astrocytes in response to CXCL12: role in neuronal toxicity. Journal of Neurochemistry, 2010, 113, 772-783.	3.9	19
236	Acetaminophen Induces Apoptosis in Rat Cortical Neurons. PLoS ONE, 2010, 5, e15360.	2.5	71
237	Pediatric HIV BioBank: A New Role of the Spanish HIV BioBank in Pediatric HIV Research. AIDS Research and Human Retroviruses, 2010, 26, 241-244.	1.1	33
238	Carbosilane Dendrimers to Transfect Human Astrocytes with Small Interfering RNA Targeting Human Immunodeficiency Virus. BioDrugs, 2010, 24, 331-343.	4.6	66
239	<i>ABCB1</i> gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics, 2010, 11, 1715-1723.	1.3	36
240	LONG-TERM EFFICACY AND SAFETY OF FOSAMPRENAVIR IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PEDIATRIC PATIENTS. Pediatric Infectious Disease Journal, 2010, 29, 563-566.	2.0	8
241	Impact of Highly Active Antiretroviral Therapy (HAART) on AIDS and Death in a Cohort of Vertically HIV Type 1-Infected Children: 1980–2006. AIDS Research and Human Retroviruses, 2009, 25, 1091-1097.	1.1	26
242	Expression of a Modified Form of CD4 Results in the Release of an Anti-HIV Factor Derived from the Env Sequence. Journal of Immunology, 2009, 183, 1188-1196.	0.8	0
243	Moesin is required for HIV-1-induced CD4-CXCR4 interaction, F-actin redistribution, membrane fusion and viral infection in lymphocytes. Journal of Cell Science, 2009, 122, 103-113.	2.0	115
244	Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation. Journal of Antimicrobial Chemotherapy, 2009, 64, 579-588.	3.0	57
245	Correlation between the Trofile(R) test and virological response to a short-term maraviroc exposure in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2009, 64, 845-849.	3.0	28
246	Changes in Gene Expression Pattern of Human Primary Macrophages Induced by Carbosilane Dendrimer 2G-NN16. Pharmaceutical Research, 2009, 26, 577-586.	3.5	37
247	Highly Efficient Transfection of Rat Cortical Neurons Using Carbosilane Dendrimers Unveils a Neuroprotective Role for HIF- $1\hat{l}_{\pm}$ in Early Chemical Hypoxia-Mediated Neurotoxicity. Pharmaceutical Research, 2009, 26, 1181-1191.	3.5	63
248	Water-stable ammonium-terminated carbosilane dendrimers as efficient antibacterial agents. Dalton Transactions, 2009, , 8704.	3.3	64
249	HIV-2 induces NF-κB activation and cyclooxygenase-2 expression in human astroglial cells. Virology, 2008, 380, 144-151.	2.4	8
250	Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation. Biochemical Pharmacology, 2008, 75, 1370-1380.	4.4	71
251	Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. Journal of Controlled Release, 2008, 132, 55-64.	9.9	154
252	Extracellular HIV-Tat Induces Cyclooxygenase-2 in Glial Cells through Activation of Nuclear Factor of Activated T Cells. Journal of Immunology, 2008, 180, 530-540.	0.8	24

#	Article	IF	Citations
253	PI4P5-Kinase ll̂ \pm Is Required for Efficient HIV-1 Entry and Infection of T Cells. Journal of Immunology, 2008, 181, 6882-6888.	0.8	38
254	Immunological Recovery and Metabolic Disorders in Severe Immunodeficiency HIV Type 1-Infected Children on Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2008, 24, 1477-1484.	1,1	11
255	Spatial pattern of HIV-1 mother-to-child-transmission in Madrid (Spain) from 1980 till now: demographic and socioeconomic factors. Aids, 2008, 22, 2199-2205.	2.2	11
256	Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children. Journal of Antimicrobial Chemotherapy, 2007, 61, 183-190.	3.0	11
257	Progesterone Inhibits HIVâ€1 Replication in Human Trophoblast Cells through Inhibition of Autocrine Tumor Necrosis Factor Secretion. Journal of Infectious Diseases, 2007, 195, 1294-1302.	4.0	20
258	Short Communication: Immune Reconstitution after Autologous Peripheral Blood Stem Cell Transplantation in HIV-Infected Patients: Might Be Better Than Expected?. AIDS Research and Human Retroviruses, 2007, 23, 543-548.	1,1	24
259	SLOW PROGRESSION OF HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS C VIRUS DISEASE IN A COHORT OF COINFECTED CHILDREN. Pediatric Infectious Disease Journal, 2007, 26, 846-849.	2.0	20
260	Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure. Aids, 2007, 21, 23-30.	2.2	20
261	Analysis of Interaction between Dendriplexes and Bovine Serum Albumin. Biomacromolecules, 2007, 8, 2059-2062.	5.4	47
262	NK Cell Increase in Neonates from the Preterm to the Full-Term Period of Gestation. Neonatology, 2007, 92, 158-163.	2.0	27
263	Persistence of proinflammatory response after severe respiratory syncytial virus disease in children. Journal of Allergy and Clinical Immunology, 2007, 119, 1547-1550.	2.9	19
264	Water-Soluble Carbosilane Dendrimers: Synthesis Biocompatibility and Complexation with Oligonucleotides; Evaluation for Medical Applications. Chemistry - A European Journal, 2007, 13, 483-495.	3.3	149
265	Effect of a bone marrow microenvironment on the ex-vivo expansion of umbilical cord blood progenitor cells. International Journal of Laboratory Hematology, 2007, 29, 58-63.	0.2	5
266	Long-Term Effects of Highly Active Antiretroviral Therapy in Pretreated, Vertically HIV Type 1-Infected Children: 6 Years of Follow-Up. Clinical Infectious Diseases, 2006, 42, 862-869.	5.8	73
267	LOW IMMUNOLOGIC RESPONSE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN NAIVE VERTICALLY HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-INFECTED CHILDREN WITH SEVERE IMMUNODEFICIENCY. Pediatric Infectious Disease Journal, 2006, 25, 365-368.	2.0	15
268	CD4+ T-Cell Immunodeficiency Is More Dependent on Immune Activation Than Viral Load in HIV-Infected Children on Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 269-276.	2.1	25
269	Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral Therapy. BMC Infectious Diseases, 2006, 6, 10.	2.9	10
270	Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. BMC Infectious Diseases, 2006, 6, 107.	2.9	8

#	Article	IF	Citations
271	Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy. BMC Infectious Diseases, 2006, 6, 112.	2.9	29
272	Lack of Association of HIV-1 Biological or Molecular Properties With Neurotropism for Brain Cells. Journal of Molecular Neuroscience, 2006, 29, 131-144.	2.3	11
273	Novel Water-Soluble Carbosilane Dendrimers: Synthesis and Biocompatibility. European Journal of Inorganic Chemistry, 2006, 2006, 1388-1396.	2.0	64
274	Clinical Outcomes Improve with Highly Active Antiretroviral Therapy in Vertically HIV Typeâ€1–Infected Children. Clinical Infectious Diseases, 2006, 43, 243-252.	5.8	72
275	Interleukin-7 levels before highly active antiretroviral therapy may predict CD4+ T-cell recovery and virological failure in HIV-infected children. Journal of Antimicrobial Chemotherapy, 2006, 57, 798-800.	3.0	11
276	Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. Journal of Antimicrobial Chemotherapy, 2006, 57, 579-582.	3.0	15
277	Tetraspanins CD9 and CD81 Modulate HIV-1-Induced Membrane Fusion. Journal of Immunology, 2006, 177, 5129-5137.	0.8	149
278	Lopinavir/r versus Nelfinavir as Salvage Therapy. Pediatric Infectious Disease Journal, 2005, 24, 392-393.	2.0	1
279	Histone Deacetylase 6 Regulates Human Immunodeficiency Virus Type 1 Infection. Molecular Biology of the Cell, 2005, 16, 5445-5454.	2.1	117
280	Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades. British Journal of Dermatology, 2005, 153, 382-389.	1.5	19
281	Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy. Journal of Antimicrobial Chemotherapy, 2005, 56, 1081-1086.	3.0	13
282	Immunological Changes after Highly Active Antiretroviral Therapy with Lopinavir–Ritonavir in Heavily Pretreated HIV-Infected Children. AIDS Research and Human Retroviruses, 2005, 21, 398-406.	1.1	10
283	Homeostatic role of ILâ€7 in HIVâ€1 infected children on HAART: Association with immunological and virological parameters. Acta Paediatrica, International Journal of Paediatrics, 2005, 94, 170-177.	1.5	7
284	Impact of Highly Active Antiretroviral Therapy on CD4+ T Cells and Viral Load of Children with AIDS: A Population-Based Study. AIDS Research and Human Retroviruses, 2004, 20, 927-931.	1.1	6
285	CD38 Expression in CD8+T Cells Predicts Virological Failure in HIV Type 1–Infected Children Receiving Antiretroviral Therapy. Clinical Infectious Diseases, 2004, 38, 412-417.	5.8	48
286	HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy. Clinical and Experimental Immunology, 2004, 137, 570-577.	2.6	41
287	Immunity in HIV-1-Infected Adults with a Previous State of Moderate-Severe Immune-Suppression and More Than 500 CD4+ T Cell After Highly Active Antiretroviral Therapy. Journal of Clinical Immunology, 2004, 24, 379-388.	3.8	16
288	Salvage Lopinavir-Ritonavir Therapy in Human Immunodeficiency Virus-Infected Children. Pediatric Infectious Disease Journal, 2004, 23, 923-930.	2.0	41

#	Article	IF	Citations
289	Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children. Journal of Clinical Immunology, 2003, 23, 279-289.	3.8	21
290	Increased interleukin-7 plasma levels are associated with recovery of CD4+ T cells in HIV-infected children. Journal of Clinical Immunology, 2003, 23, 401-406.	3.8	21
291	Transmission of HIV-1 infection between trophoblast placental cells and T-cells take place via an LFA-1-mediated cell to cell contact. Virology, 2003, 307, 266-277.	2.4	62
292	Stimulated proliferative responses in vertically HIV-infected children on HAART correlate with clinical and immunological markers. Clinical and Experimental Immunology, 2003, 131, 130-137.	2.6	5
293	Preserved immune system in long-term asymptomatic vertically HIV-1 infected children. Clinical and Experimental Immunology, 2003, 132, 105-112.	2.6	26
294	Neuroprotective effects of early antiretrovirals in vertical HIV infection. Pediatric Neurology, 2003, 29, 218-221.	2.1	32
295	Viral Load and CD4+ T Lymphocyte Response to Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Children: An Observational Study. Clinical Infectious Diseases, 2003, 37, 1216-1225.	5.8	54
296	CD8+ T-Cell Numbers Predict the Response to Antiviral Therapy in HIV-1-Infected Children. Pediatric Research, 2003, 53, 309-312.	2.3	6
297	Characterizing Immune Reconstitution after Long-Term Highly Active Antiretroviral Therapy in Pediatric AIDS. AIDS Research and Human Retroviruses, 2002, 18, 1395-1406.	1.1	32
298	Production of New T Cells by Thymus in Children: Effect of HIV Infection and Antiretroviral Therapy. Pediatric Research, 2002, 52, 207-212.	2.3	25
299	Impact of antiretroviral protocols on dynamics of AIDS progression markers. Archives of Disease in Childhood, 2002, 86, 119-124.	1.9	19
300	Candida albicans infection enhances immunosuppression induced by cyclophosphamide by selective priming of suppressive myeloid progenitors for NO production. Cellular Immunology, 2002, 218, 46-58.	3.0	23
301	Dynamics of progression markers in a non-study population of human immunodeficiency virus-1 vertically infected infants with different antiretroviral treatments. Acta Paediatrica, International Journal of Paediatrics, 2002, 91, 776-782.	1.5	4
302	Immunological recovery after 3 years' antiretroviral therapy in HIV-1-infected children. Aids, 2002, 16, 483-486.	2.2	21
303	Effects of highly active antiretroviral therapy on thymical reconstitution of CD4 T lymphocytes in vertically HIV-infected children. Aids, 2002, 16, 1181-1183.	2.2	22
304	Viral phenotype affects the thymic production of new T cells in HIV-1-infected children. Aids, 2001, 15, 1959-1963.	2.2	45
305	Na $ ilde{A}^-$ ve and memory CD4+ T cells and T cell activation markers in HIV-1 infected children on HAART. Clinical and Experimental Immunology, 2001, 125, 266-273.	2.6	35
306	Regulation of Human Immunodeficiency Virus Type 1 Replication in Human T Lymphocytes by Nitric Oxide. Journal of Virology, 2001, 75, 4655-4663.	3.4	34

#	Article	IF	CITATIONS
307	Association of CD8+T Lymphocyte Subsets with the Most Commonly Used Markers to Monitor HIV Type 1 Infection in Children Treated with Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2001, 17, 525-532.	1.1	22
308	Disruption in cytokine and chemokine production by T-cells in vertically HIV-1-infected children. Acta Paediatrica, International Journal of Paediatrics, 2001, 90, 989-997.	1.5	8
309	Early myeloid cells are high producers of nitric oxide upon CD40 plus IFN-γ stimulation through a mechanism dependent on endogenous TNF-α and IL-1α. European Journal of Immunology, 2000, 30, 1263-1271.	2.9	46
310	Clinical Relevance of Cytokine Production in HIV-1 Infection in Children on Antiretroviral Therapy. Scandinavian Journal of Immunology, 2000, 52, 634-640.	2.7	11
311	Predictive Markers of Clinical Outcome in Vertically HIV-1–Infected Infants. A Prospective Longitudinal Study. Pediatric Research, 2000, 47, 509-515.	2.3	51
312	Antiretroviral treatment induces a shift to type-2 cytokine responses in HIV-1 infected pregnant women. European Cytokine Network, 2000, 11, 647-53.	2.0	3
313	Correlation of Viral Load and CD8 T-Lymphocytes with Development of Neurological Manifestations in Vertically HIV-1-Infected Infants. A Prospective Longitudinal Study. Neuropediatrics, 1999, 30, 197-204.	0.6	20
314	HIV-1 Infection Induces Differentiation of Immature Neural Cells through Autocrine Tumor Necrosis Factor and Nitric Oxide Production. Virology, 1999, 261, 193-204.	2.4	27
315	Adenoidal tissue mass as a clinical guide of disease evolution in vertically HIV-1 infected children. International Journal of Pediatric Otorhinolaryngology, 1999, 51, 145-155.	1.0	5
316	The role of tumour necrosis factor, interleukin 6, interferon- \hat{l}^3 and inducible nitric oxide synthase in the development and pathology of the nervous system. Progress in Neurobiology, 1998, 56, 307-340.	5.7	358
317	Retroviral Vector-Mediated Expression in Primary Human T Cells of an Endoplasmic Reticulum-Retained CD4 Chimera Inhibits Human Immunodeficiency Virus Type-1 Replication. Human Gene Therapy, 1998, 9, 1345-1357.	2.7	11
318	Inhibition of Phosphodiesterase Type IV Suppresses Human Immunodeficiency Virus Type 1 Replication and Cytokine Production in Primary T Cells: Involvement of NF-κB and NFAT. Journal of Virology, 1998, 72, 4712-4720.	3.4	56
319	Replication of human immunodeficiency virus-1 in primary human T cells is dependent on the autocrine secretion of tumor necrosis factor through the control of nuclear factor- $\hat{\Gamma}^0$ B activation. Journal of Allergy and Clinical Immunology, 1997, 100, 838-845.	2.9	33
320	Induction of Adhesion/Differentiation of Human Neuroblastoma Cells by Tumour Necrosis Factor-α Requires the Expression of an Inducible Nitric Oxide Synthase. European Journal of Neuroscience, 1997, 9, 1184-1193.	2.6	23
321	Immunological and virological markers of disease progression in HIVâ€infected children. Acta Paediatrica, International Journal of Paediatrics, 1997, 86, 46-51.	1.5	12
322	Megalomicin Inhibits HIV-1 Replication and Interferes with gp160 Processing. Virology, 1997, 239, 303-314.	2.4	19
323	Quantification of low levels of human immunodeficiency virus (HIV) type 1 RNA in P24 antigen-negative, asymptomatic, HIV-positive patients by PCR. Journal of Clinical Microbiology, 1996, 34, 404-408.	3.9	10
324	Relationship of Virologic, Immunologic, and Clinical Parameters in Infants with Vertically Acquired Human Immunodeficiency Virus Type 1 Infection. Pediatric Research, 1996, 40, 597-602.	2.3	63

MÂA ÃNGELES

#	Article	IF	CITATIONS
325	Control of T lymphocyte activation and IL-2 receptor expression by endogenously secreted lymphokines. Journal of Immunology, 1994, 152, 5714-22.	0.8	57
326	SARS-CoV2 Infection During Pregnancy Causes Persistent Immune Abnormalities in Women Without Affecting the Newborns. Frontiers in Immunology, $0,13,13$	4.8	7
327	Nutritional Supplementation to Increase Influenza Vaccine Response in Children Living With HIV: A Pilot Clinical Trial. Frontiers in Pediatrics, 0, 10 , .	1.9	0